Cargando…

Quantitative liver SPECT/CT is a novel tool to assess liver function, prognosis, and response to treatment in cirrhosis

BACKGROUND: Functional liver reserve is an important determinant of survival in cirrhosis. The traditional indocyanine green test (ICG) is cumbersome. Hence, we developed and validated a novel liver imaging, a hybrid of SPECT and CT (Q-SPECT/CT), for evaluating disease severity, outcomes, and respon...

Descripción completa

Detalles Bibliográficos
Autores principales: Kaur, Amritjyot, Verma, Nipun, Singh, Baljinder, Kumar, Ajay, Kumari, Sunita, De, Arka, Sharma, Ratti Ram, Singh, Virendra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10073445/
https://www.ncbi.nlm.nih.gov/pubmed/37035316
http://dx.doi.org/10.3389/fmed.2023.1118531
_version_ 1785019566996324352
author Kaur, Amritjyot
Verma, Nipun
Singh, Baljinder
Kumar, Ajay
Kumari, Sunita
De, Arka
Sharma, Ratti Ram
Singh, Virendra
author_facet Kaur, Amritjyot
Verma, Nipun
Singh, Baljinder
Kumar, Ajay
Kumari, Sunita
De, Arka
Sharma, Ratti Ram
Singh, Virendra
author_sort Kaur, Amritjyot
collection PubMed
description BACKGROUND: Functional liver reserve is an important determinant of survival in cirrhosis. The traditional indocyanine green test (ICG) is cumbersome. Hence, we developed and validated a novel liver imaging, a hybrid of SPECT and CT (Q-SPECT/CT), for evaluating disease severity, outcomes, and response to treatment in decompensated cirrhosis (DC). METHODS: We recruited a cohort of DC patients at a tertiary institute between 2016–2019. First, we standardized the Q-SPECT/CT across a predefined range of volumes through phantom experiments. Then we performed clinical and laboratory evaluations, ICG test (retention at 15 min), and Q-SPECT/CT at baseline and 12 months of granulocyte colony-stimulating factor (G-CSF) and standard medical treatment (SMT). RESULTS: In 109 DC patients, 87.1% males, aged 51 ± 10 years, MELD: 14 (7–21), the percent quantitative liver uptake (%QLU) on Q-SPECT/CT exhibited a strong correlation with CTP (r = −0.728, p < 0.001), MELD (r = −0.743; p < 0.001) and ICG-R-15 (r = −0.720, p < 0.001) at baseline. %QLU had the maximum discrimination (AUC: 0.890–0.920), sensitivity (88.9–90.3%), specificity (81.2–90.7%), and accuracy (85.8–89.4%) than liver volumes on Q-SPECT/CT or ICG test for classifying patients in CTP/MELD based prognostic categories. A significant increase in %QLU (26.09 ± 10.06 to 31.2 ± 12.19, p = 0.001) and improvement in CTP/MELD correlated with better survival of G-CSF treated DC patients (p < 0.05). SMT did not show any improvement in Q-SPECT/CT or clinical severity scores (p > 0.05). %QLU > 25 (adj.H.R.: 0.234, p = 0.003) and G-CSF treatment (adj.H.R.: 0.414, p = 0.009) were independent predictors of better 12-months survival in DC. CONCLUSION: Q-SPECT/CT (%QLU) is a novel non-invasive, diagnostic, prognostic, and theragnostic marker of liver reserve and its functions in cirrhosis patients. CLINICAL TRIAL REGISTRATION: Clinicaltrials.gov, NCT02451033 and NCT03415698.
format Online
Article
Text
id pubmed-10073445
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-100734452023-04-06 Quantitative liver SPECT/CT is a novel tool to assess liver function, prognosis, and response to treatment in cirrhosis Kaur, Amritjyot Verma, Nipun Singh, Baljinder Kumar, Ajay Kumari, Sunita De, Arka Sharma, Ratti Ram Singh, Virendra Front Med (Lausanne) Medicine BACKGROUND: Functional liver reserve is an important determinant of survival in cirrhosis. The traditional indocyanine green test (ICG) is cumbersome. Hence, we developed and validated a novel liver imaging, a hybrid of SPECT and CT (Q-SPECT/CT), for evaluating disease severity, outcomes, and response to treatment in decompensated cirrhosis (DC). METHODS: We recruited a cohort of DC patients at a tertiary institute between 2016–2019. First, we standardized the Q-SPECT/CT across a predefined range of volumes through phantom experiments. Then we performed clinical and laboratory evaluations, ICG test (retention at 15 min), and Q-SPECT/CT at baseline and 12 months of granulocyte colony-stimulating factor (G-CSF) and standard medical treatment (SMT). RESULTS: In 109 DC patients, 87.1% males, aged 51 ± 10 years, MELD: 14 (7–21), the percent quantitative liver uptake (%QLU) on Q-SPECT/CT exhibited a strong correlation with CTP (r = −0.728, p < 0.001), MELD (r = −0.743; p < 0.001) and ICG-R-15 (r = −0.720, p < 0.001) at baseline. %QLU had the maximum discrimination (AUC: 0.890–0.920), sensitivity (88.9–90.3%), specificity (81.2–90.7%), and accuracy (85.8–89.4%) than liver volumes on Q-SPECT/CT or ICG test for classifying patients in CTP/MELD based prognostic categories. A significant increase in %QLU (26.09 ± 10.06 to 31.2 ± 12.19, p = 0.001) and improvement in CTP/MELD correlated with better survival of G-CSF treated DC patients (p < 0.05). SMT did not show any improvement in Q-SPECT/CT or clinical severity scores (p > 0.05). %QLU > 25 (adj.H.R.: 0.234, p = 0.003) and G-CSF treatment (adj.H.R.: 0.414, p = 0.009) were independent predictors of better 12-months survival in DC. CONCLUSION: Q-SPECT/CT (%QLU) is a novel non-invasive, diagnostic, prognostic, and theragnostic marker of liver reserve and its functions in cirrhosis patients. CLINICAL TRIAL REGISTRATION: Clinicaltrials.gov, NCT02451033 and NCT03415698. Frontiers Media S.A. 2023-03-22 /pmc/articles/PMC10073445/ /pubmed/37035316 http://dx.doi.org/10.3389/fmed.2023.1118531 Text en Copyright © 2023 Kaur, Verma, Singh, Kumar, Kumari, De, Sharma and Singh. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Medicine
Kaur, Amritjyot
Verma, Nipun
Singh, Baljinder
Kumar, Ajay
Kumari, Sunita
De, Arka
Sharma, Ratti Ram
Singh, Virendra
Quantitative liver SPECT/CT is a novel tool to assess liver function, prognosis, and response to treatment in cirrhosis
title Quantitative liver SPECT/CT is a novel tool to assess liver function, prognosis, and response to treatment in cirrhosis
title_full Quantitative liver SPECT/CT is a novel tool to assess liver function, prognosis, and response to treatment in cirrhosis
title_fullStr Quantitative liver SPECT/CT is a novel tool to assess liver function, prognosis, and response to treatment in cirrhosis
title_full_unstemmed Quantitative liver SPECT/CT is a novel tool to assess liver function, prognosis, and response to treatment in cirrhosis
title_short Quantitative liver SPECT/CT is a novel tool to assess liver function, prognosis, and response to treatment in cirrhosis
title_sort quantitative liver spect/ct is a novel tool to assess liver function, prognosis, and response to treatment in cirrhosis
topic Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10073445/
https://www.ncbi.nlm.nih.gov/pubmed/37035316
http://dx.doi.org/10.3389/fmed.2023.1118531
work_keys_str_mv AT kauramritjyot quantitativeliverspectctisanoveltooltoassessliverfunctionprognosisandresponsetotreatmentincirrhosis
AT vermanipun quantitativeliverspectctisanoveltooltoassessliverfunctionprognosisandresponsetotreatmentincirrhosis
AT singhbaljinder quantitativeliverspectctisanoveltooltoassessliverfunctionprognosisandresponsetotreatmentincirrhosis
AT kumarajay quantitativeliverspectctisanoveltooltoassessliverfunctionprognosisandresponsetotreatmentincirrhosis
AT kumarisunita quantitativeliverspectctisanoveltooltoassessliverfunctionprognosisandresponsetotreatmentincirrhosis
AT dearka quantitativeliverspectctisanoveltooltoassessliverfunctionprognosisandresponsetotreatmentincirrhosis
AT sharmarattiram quantitativeliverspectctisanoveltooltoassessliverfunctionprognosisandresponsetotreatmentincirrhosis
AT singhvirendra quantitativeliverspectctisanoveltooltoassessliverfunctionprognosisandresponsetotreatmentincirrhosis